BRPI0410646A - composições farmacêuticas de acitretina e processo para sua preparação - Google Patents

composições farmacêuticas de acitretina e processo para sua preparação

Info

Publication number
BRPI0410646A
BRPI0410646A BRPI0410646-6A BRPI0410646A BRPI0410646A BR PI0410646 A BRPI0410646 A BR PI0410646A BR PI0410646 A BRPI0410646 A BR PI0410646A BR PI0410646 A BRPI0410646 A BR PI0410646A
Authority
BR
Brazil
Prior art keywords
acitretin
pharmaceutical compositions
preparation
milling
spraying
Prior art date
Application number
BRPI0410646-6A
Other languages
English (en)
Inventor
Shashiakanth Isloor
Sanjeev Kumar Sethi
Rajiv Malik
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of BRPI0410646A publication Critical patent/BRPI0410646A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSIçõES FARMACêUTICAS DE ACITRETINA E PROCESSO PARA SUA PREPARAçãO". A presente invenção refere-se a composições farmacêuticas estáveis de acitretina com características de biodisponibilidade significativamente melhoradas. As composições farmacêuticas incluem uma dispersão de acitretina sólida micronizada com um ou mais modificadores de superfície. Também são proporcionados processos para preparação de composições a partir da pulverização ou moagem de acitretina na presença de um modificador de superfície hidrofílica.
BRPI0410646-6A 2003-05-20 2004-05-21 composições farmacêuticas de acitretina e processo para sua preparação BRPI0410646A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN713DE2003 2003-05-20
PCT/IB2004/001636 WO2004103346A1 (en) 2003-05-20 2004-05-21 Pharmaceutical compositions of acitretin

Publications (1)

Publication Number Publication Date
BRPI0410646A true BRPI0410646A (pt) 2006-07-04

Family

ID=33463015

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410646-6A BRPI0410646A (pt) 2003-05-20 2004-05-21 composições farmacêuticas de acitretina e processo para sua preparação

Country Status (4)

Country Link
US (1) US20070099996A1 (pt)
BR (1) BRPI0410646A (pt)
MX (1) MXPA05012632A (pt)
WO (1) WO2004103346A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013521318A (ja) * 2010-03-08 2013-06-10 ラティオファルム ゲー・エム・ベー・ハー ダビガトランエテキシラートを含有する医薬組成物
EP2663294B1 (en) 2011-01-11 2015-09-30 Capsugel Belgium NV New hard capsules comprising pullulan
SG11201400977QA (en) * 2011-10-05 2014-04-28 Douglas Pharmaceuticals Ltd Pharmaceutical methods and topical compositions containing acitretin
AU2015292212B2 (en) 2014-07-25 2019-03-14 Laurent Pharmaceuticals Solid oral formulation of fenretinide
CN105362230B (zh) * 2015-11-27 2018-08-24 中牧南京动物药业有限公司 基于固体分散体技术制备盐酸沙拉沙星可溶性粉的工艺方法
CA3061267A1 (en) * 2017-04-07 2018-10-11 Maa Laboratories, Inc. Methods of improving the solubility and bioavailability of therapeutic agents
US11319566B2 (en) 2017-04-14 2022-05-03 Capsugel Belgium Nv Process for making pullulan
HRP20250979T1 (hr) 2017-04-14 2025-10-24 Capsugel Belgium Nv Pululan kapsule
CN112162048B (zh) * 2020-09-28 2022-07-29 重庆华邦胜凯制药有限公司 分离测定阿维a及其杂质的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105681A (en) * 1975-08-01 1978-08-08 Hoffmann-La Roche Inc. 9-phenyl 5,6-dimethyl-nona-2,4,6,8-tetraeonic acid compounds
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
GB8403359D0 (en) * 1984-02-08 1984-03-14 Erba Farmitalia Pharmaceutical compositions
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
AU670777B2 (en) * 1992-04-16 1996-08-01 Ortho Pharmaceutical Corporation Aqueous gel vehicles for retinoids
TW272187B (pt) * 1992-05-20 1996-03-11 Hoffmann La Roche
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
CA2281837A1 (en) * 1999-09-07 2001-03-07 Bernard Charles Sherman Solid pharmaceutical composition comprising a retinoid and polyethylene glycol
IN192188B (pt) * 2000-06-16 2004-03-13 Ranbaxy Lab Ltd

Also Published As

Publication number Publication date
MXPA05012632A (es) 2006-02-22
WO2004103346A1 (en) 2004-12-02
US20070099996A1 (en) 2007-05-03

Similar Documents

Publication Publication Date Title
BRPI0411916A (pt) imidazoquinolinas substituìdas por sulfonamida
WO2007002516A3 (en) Improved dosage forms for movement disorder treatment
TW200612892A (en) Novel compounds
WO2007089745A3 (en) Novel compounds with high therapeutic index
EP1726299A3 (en) Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
BRPI0417341A (pt) fator ix glicopeguilado
IL226857A0 (en) Recombinant proteins that have undergone n-site glycosylation in prokaryotic cells
CA2340405A1 (en) Substituted 4-amino-2-aryl-pyrimidines, their production and use and pharmaceutical preparations containing same
EP1798231A3 (fr) Produits intermédiaires dans la préparation de composés anti-bactériens
BR0308056A (pt) Composto, pró-droga, método para a produção de um efeito antibacteriano em um animal de sangue quente, uso de um composto, composição farmacêutica, e, processo para a preparação de um composto
BR0210028A (pt) Agentes antibacterianos
EP1784388B8 (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
WO2006029081A3 (en) Nucleoside-lipid conjugates, their method of preparation and uses thereof
WO2002068680A3 (en) Compositions and methods for regulating endogenous inhibitor of atp synthase, including treatment for diabetes
DE59913103D1 (de) Substituierte 4-amino-2-aryl-cyclopenta ädüpyrimidine, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate
BR0208534A (pt) Processo para preparação de 4,6-diaminopirimido[5,4-d]pirimidinas
MA28849B1 (fr) Procede pour la preparation d'un piroxicame : compose d'inclusion a base de beta-cyclodextrine
ATE255565T1 (de) Substituierte 4-amino-2-aryltetrahydrochinazoline,deren herstellung, deren verwendung und diese enthaltende pharmazeutische zusammenstellungen
BRPI0508177A (pt) composto, processo para a produção do composto, composição farmacêutica, uso do composto método para o tratamento de uma doença e produto de combinação
CY1110401T1 (el) Παραγωγα των 1-φαινυλαλκανοκαρβοξυλικων οξεων για την αντιμετωπιση των νευροεκφυλιστικων νοσων
BRPI0416672A (pt) método de produção de uma composição granular contendo lecitina e composição granular contendo lecitina
BR0316782A (pt) Produto de leite fermentado, processo para preparação de um produto de leite fermentado e uso da linhagem cnrz 244 de lactobacillus helveticus
WO2006117211A3 (en) Urea derivatives methods for their manufacture and uses thereof
TW200640471A (en) Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
MXPA05012632A (es) Composiciones farmaceuticas de acitretin.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired